Literature DB >> 24801085

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.

Sha Li1, Yuan-Lin Guo1, Rui-Xia Xu1, Yan Zhang1, Cheng-Gang Zhu1, Jing Sun1, Ping Qing1, Na-Qiong Wu1, Jian-Jun Li2.   

Abstract

Entities:  

Keywords:  Atherosclerosis; Gensini score; Lipid; Proprotein convertase subtilisin/kexin type 9

Mesh：

Substances：

Year:  2014        PMID： 24801085     DOI： 10.1016/j.ijcard.2014.04.224

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  11 in total

1.  Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.

Authors:  S Li; R X Xu; Y Zhang; Y L Guo; C G Zhu; G Liu; Q Dong; J J Li
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

Review 2.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

3.  Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.

Authors:  Naif A M Almontashiri; Ragnar O Vilmundarson; Nima Ghasemzadeh; Sonny Dandona; Robert Roberts; Arshed A Quyyumi; Hsiao-Huei Chen; Alexandre F R Stewart
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

4.  Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.

Authors:  Sandeep Kumar; Dong-Won Kang; Amir Rezvan; Hanjoong Jo
Journal:  Lab Invest       Date:  2017-05-15       Impact factor: 5.662

5.  Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.

Authors:  I-Chih Chen; Wei-Kung Tseng; Yi-Heng Li; Shih-Ya Tseng; Ping-Yen Liu; Ting-Hsing Chao
Journal:  Oncotarget       Date:  2017-11-14

6.  Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.

Authors:  Ting-Hsing Chao; I-Chih Chen; Yi-Heng Li; Po-Tseng Lee; Shih-Ya Tseng
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

7.  Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.

Authors:  Tsuyoshi Nozue; Hiroaki Hattori; Kazuyuki Ogawa; Takeshi Kujiraoka; Tadao Iwasaki; Tsutomu Hirano; Ichiro Michishita
Journal:  Lipids Health Dis       Date:  2016-09-22       Impact factor: 3.876

8.  Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.

Authors:  Jian-Jun Li; Sha Li; Yan Zhang; Rui-Xia Xu; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Ping Qing; Ying Gao; Jing Sun; Geng Liu; Qian Dong
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.

Authors:  Jing Gao; Hai-Bo Wang; Jian-Yong Xiao; Min Ren; Kathleen Heather Reilly; Yu-Ming Li; Yin Liu
Journal:  BMJ Open       Date:  2018-07-10       Impact factor: 2.692

10.  Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.

Authors:  Jing Gao; Ya-Nan Yang; Zhuang Cui; Si-Yuan Feng; Jing Ma; Chang-Ping Li; Yin Liu
Journal:  Lipids Health Dis       Date:  2021-05-27       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.